Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
Abstract Background Immune checkpoint inhibitors are effective therapies for a wide range of malignancies. Their increased use has led to a wide range of immune-related adverse effects including skin, gastrointestinal, pulmonary, endocrine, cardiac, and neurologic complications. Case presentation We...
Main Authors: | Jason Cham, Daniel Ng, Laura Nicholson |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13256-021-02858-7 |
Similar Items
-
Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
by: Maki Todo, et al.
Published: (2020-01-01) -
Presence of Multiple Autoimmune Antibodies Involved in Concurrent Myositis and Myocarditis and Myasthenia Gravis Without Thymoma: A Case Report
by: Zhijian Zhou, et al.
Published: (2019-07-01) -
A systematic review of myasthenia gravis complicated with myocarditis
by: Wei Cheng, et al.
Published: (2021-08-01) -
Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
by: Yue-Bei Luo, et al.
Published: (2021-08-01) -
Contracturing Granulomatous Myositis with Recurrent Malignant Thymoma and Myasthenia Gravis: A Case Report
by: Ching On Luk, et al.
Published: (2021-07-01)